Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

72.10
-3.0300-4.03%
Post-market: 72.100.00000.00%19:30 EDT
Volume:1.42M
Turnover:102.58M
Market Cap:3.52B
PE:-16.68
High:75.44
Open:75.21
Low:70.68
Close:75.13
52wk High:151.02
52wk Low:44.42
Shares:48.77M
Float Shares:29.72M
Volume Ratio:1.16
T/O Rate:4.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-275.10
PE(LYR):-19.02

Loading ...

BRIEF-Celcuity Q1 Adjusted EPS USD -0.86 Vs. IBES Estimate USD -1.05

Reuters
·
May 15

Celcuity Q1 EPS USD -0.97

THOMSON REUTERS
·
May 15

Celcuity Inc: Expect Cash, Cash Equivalents, Investments & Drawdowns on Debt Facility to Finance Operations Through 2027

THOMSON REUTERS
·
May 15

Analysts Are Bullish on Top Healthcare Stocks: Celcuity (CELC), Rubicon Organics (ROMJF)

TIPRANKS
·
May 15

Celcuity announces amendments to VIKTORIA-2 clinical trial of gedatolisib

TIPRANKS
·
May 14

Stock Track | Celcuity Soars 5.04% Intraday on FDA Priority Review and Expanded Phase 3 Trial for Breast Cancer Drug

Stock Track
·
May 14

Celcuity Expands Gedatolisib Phase 3 Program in First-Line Breast Cancer Setting

MT Newswires Live
·
May 14

Celcuity Inc - FDA Grants Priority Review to Celcuity's Nda for Gedatolisib With Pdufa Date July 17, 2026

THOMSON REUTERS
·
May 14

Celcuity Inc - Submits Patent Application for Subcutaneous Formulation of Gedatolisib

THOMSON REUTERS
·
May 14

Celcuity Inc - Holds Type B Meeting With FDA on Amended Phase 3 Trial Design

THOMSON REUTERS
·
May 14

Celcuity’s Phase 3 Viktoria-2 Trial of Gedatolisib as a First-Line Treatment for Hr+/Her2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

THOMSON REUTERS
·
May 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 13

Celcuity Inc expected to post a loss of $1.05 a share - Earnings Preview

Reuters
·
May 13

Celcuity to report Q1 results, host webcast and conference call after market close

Reuters
·
May 07

Is It Too Late To Consider Celcuity (CELC) After Its Recent Share Price Surge?

Simply Wall St.
·
May 07

Celcuity director David Dalvey reports disposal of 25,000 shares worth $3.52 million

Reuters
·
May 07

Celcuity director Richard E. Buller disposes of 9,000 common shares for $1,260,514

Reuters
·
May 07

Top Midday Gainers

MT Newswires Live
·
May 05

Celcuity rises 17.1%

TIPRANKS
·
May 04

Celcuity price target raised to $189 from $141 at Craig-Hallum

TIPRANKS
·
May 04